Methods and compositions for treating melanoma
View Patent ↗A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM1 antagonist, or a combination thereof
1. A method of inhibiting melanoma cell growth in a patient diagnosed with a melanoma tumor expressing GRM1 comprising administering to said patient an amount of a glutamate release inhibitor, a GRM1 antagonist, or a combination thereof, that is effective to decrease the metabolic activity of said tumor thereby inhibiting melanoma cell growth.
2. The method of claim 1 , wherein said GRM1 antagonist is a competitive or noncompetitive GRM1 antagonist.
3. The method of claim 1 , wherein said glutamate release inhibitor is 2-amino-6-trifluoromethoxybenzothiazole (riluzole).
4. The method of claim 1 , further comprising administering to said patient an anti-proliferative agent, a chemotherapeutic agent, a B-raf inhibitor, a PI3K inhibitor, an antiapoptosis inhibitor, a benzoquinone ansamycin antibiotic, an antiangiogenesis agent, or a combination thereof.
5. The method of claim 4 , wherein said chemotherapeutic agent is selected from the group consisting of 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide (temozolomide); 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (dacarbazine); platinum, diammine [1,1-cyclobutane-dicarboxylato (2-)-[0,0′]-(SP-4-2) (carboplatin); and 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (paclitaxel).
6. The method of claim 4 , wherein said B-raf inhibitor is 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate (sorafenib).
7. The method of claim 4 , wherein said antiapoptosis inhibitor is a Bcl-2 inhibitor.
8. The method of claim 4 , wherein said benzoquinone ansamycin antibiotic is geldanamycin or 17-N-allylamino-17-demethoxygeldanamycin.
9. The method of claim 4 , wherein said antiangiogenesis agent is bevacizumab.
10. The method of claim 1 , wherein said glutamate release inhibitor or GRM1 antagonist is administered prior to surgical excision of at least a portion of the melanoma.
11. The method of claim 1 , wherein said glutamate release inhibitor or GRM1 antagonist is administered following surgical excision of at least a portion of the melanoma.
12. The method of claim 1 , wherein said glutamate release inhibitor or GRM1 antagonist is administered in a chronic dose.
13. The method of claim 1 , wherein said glutamate release inhibitor or GRM1 antagonist is administered orally, intravenously, or intraperitoneally.